RNS Number: 0929 D Hutchison China Meditech Limited 21 June 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0922 D Hutchison China Meditech Limited 21 June 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8093 C Hutchison China Meditech Limited 19 June 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Hutchison China MediTech (HCM.L) 430p £2,788.29m Hutchison China MediTech Limited announced that the independent Data Monitoring Committee ("IDMC") of the Phase III pivotal study of surufatinib in advanced neuroendoc-rine tumors - extra-pancreatic ("SANET-ep") has completed a planned interim analysis. The IDMC determined that the study has already met the pre-defined primary endpoint of progression free survival ("PFS") and as a result the study will be stopped. Chi-Med will now arrange for a pre-New Drug Application ("NDA") meeting with the China National Medical Products Administration (NMPA) to discuss the preparation of the NDA for surufatinib for this indication. We intend to submit the results of the SANET-ep study for presentation at an upcoming scientific conference.
RNS Number: 2896 C Hutchison China Meditech Limited 14 June 2019 Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early. London: Friday, June 14, 2019: Hutchison China MediTech Limited today announces that the independent...
RNS Number: 9447 B Hutchison China Meditech Limited 12 June 2019. Block Admission Applications and Total Voting Rights. London: Wednesday, June 12, 2019: Hutchison China MediTech Limited today announces that the following applications have been made to the London Stock Exchange plc for the block admission of ordinary shares, par value of US $0.10 each to be...
RNS Number: 6989 B Hutchison China Meditech Limited 10 June 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 6986 B Hutchison China Meditech Limited 10 June 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
London: Thursday, June 6, 2019: Hutchison China MediTech Limited today filed the Post Hearing Information Pack with the Stock Exchange of Hong Kong Limited in connection with a proposed listing of its ordinary shares on the Main Board of the SEHK and concurrent global offering of ordinary shares as previously announced on April 15, 2019. Dual-listed on the AIM...
RNS Number: 8225 A Hutchison China Meditech Limited 31 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 8211 A Hutchison China Meditech Limited 31 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
London: Wednesday, May 29, 2019: Hutchison China MediTech Limited today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting held on May 29, 2019 were duly passed. Following the passing of Resolution 1, Chi-Med confirms that each of Chi-Med's ordinary shares of US $1.00 each will be subdivided into 10 new...
London: Wednesday, May 22, 2019: Hutchison China MediTech Limited announces that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015.. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an...
Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference on May 15 th and 16 th, featuring live webcast presentations from international companies with American Depositary Receipt programs in the US. Representatives from participating companies based in Germany, Norway, Denmark, China, Switzerland, Australia,...
London: Friday, May 3, 2019: Hutchison China MediTech Limited today announces that an Extraordinary General Meeting is to be held at 11:00 a.m. London time on Wednes day, May 29, 2019. In connection with the Company's previously announced potential listing on The Stock Exchange of Hong Kong Limited and global offering of ordinary shares, the Company is...
RNS Number: 9828 W Hutchison China Meditech Limited 24 April 2019. Results of Annual General Meeting. London: Wednesday, April 24, 2019: Hutchison China MediTech Limited today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting held on April 24, 2019 were duly passed.
Hutchison China Meditech Limited (HCM.L) Announced that it has submitted a listing application on Form A1 to The Stock Exchange of Hong Kong (SEHK) to apply for the listing of, and permission to deal in, its shares on the Main Board of the SEHK. In connection with the proposed listing on the SEHK, the company proposes to undertake a global offering of its shares. Currently, the company's Shares are admitted for trading on the AIM market of the London Stock Exchange and its American Depositary Shares (ADS), each representing one-half of one share, are listed on the Nasdaq Global Select Market.
London: Monday, April 15, 2019: Hutchison China MediTech Limited today filed an application with the Stock Exchange of Hong Kong Limited in connection with a proposed listing of its ordinary shares on the Main Board of the SEHK. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an...
Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering. Hong Kong: Monday, April 15, 2019: Hutchison China MediTech Limited, the commercial-stage biopharmaceutical company focused on discovery, development and commercialization of targeted therapies and immunotherapies for oncology and immunological diseases, is...
Hutchison China Meditech (HCM) bounced on news of a new Chinese clinical trial comparing cancer drug surufatinib with chemotherapy drug capecitabine in patients with advanced biliary tract cancer. The primary endpoint is overall survival, with secondary targets in place around progression free survival rates, duration of response in patients and overall quality of life. We remain buyers.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    66.66M

Classification

Market Indices-

Locations

HQ
22nd Floor, Hutchison House
10 Harcourt Road
Hong Kong
Watchlist